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Objective: Local vancomycin treatment has been shown to decrease sternal wound complication rates. Whether a similar
effect can be achieved at other surgical sites is unknown. This study investigates the effect of local vancomycin on inguinal
wound complication rates after vascular procedures.
Methods: Retrospective analysis was performed on 454 patients who underwent open aortofemoral or infrainguinal
vascular procedures between 2006 and 2011. Patients received preoperative systemic antibiotics either alone (group A) or
in conjunction with intraoperative wound application of vancomycin powder and irrigation (group B). Inguinal wound
infection and dehiscence over a 30-day period were recorded. Fisher exact test and multivariate regression analyses were
performed.
Results: There were 211 patients in group A and 243 patients in group B. Both groups had similar demographics and
operative characteristics. There was a small but statistically signiﬁcant decrease in the 30-day incidence of overall wound
infections (25.1% vs 17.2%; P [ .049) for group B patients. This was primarily due to a decreased rate in superﬁcial
infections (18.9% vs 11.5%; P[ .033). No signiﬁcant difference in the incidence of deep wound infections (6.1% vs 5.7%;
P [ .692) or overall dehiscence rates (22.2% vs 17.7%; P [ .239) was detected. On multivariate analysis, history of
chronic obstructive pulmonary disease and increased body mass index signiﬁcantly increased risk of both infection and
dehiscence. Medically optimized coronary artery disease was associated with less risk for dehiscence.
Conclusions: Addition of intraoperative local vancomycin did not improve the rates of inguinal wound dehiscence or deep
infections but had a positive impact on superﬁcial wound infections. (J Vasc Surg 2013;57:1079-83.)Inguinal wound complications occurring after vascular
procedures contribute signiﬁcantly to postoperative mor-
bidity and may substantially increase health care costs.
These complications range from superﬁcial and deep
surgical site infections to dehiscence, and they are most
commonly due to gram-positive bacteria, such as Staphylo-
coccus aureus or Staphylococcus epidermis. Methicillin-
resistant Staphylococcus aureus (MRSA) is emerging as the
prevalent pathogen in these infections, with involvement
in more than one-third of cases.1
In an attempt to decrease the rate of these complica-
tions, surgeons in a variety of operative ﬁelds have used
intraoperative local antibiotic treatment before wound
closure. Although such treatment has been shown to
decrease sternal wound complication rates in median ster-
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investigates the effect of intraoperative local vancomycin
treatment on 30-day inguinal wound complication rates
after vascular procedures.
METHODS
We conducted a retrospective review of 454 consecu-
tive patients who underwent open aortofemoral or infrain-
guinal procedures between 2006 and 2011. Patients
with already infected groin wounds or infected prosthetic
conduits were excluded from the study. All patients
received intravenous weight-based prophylactic antibiotic
therapy within 1 hour before incision, and this therapy
was redosed according to protocol for lengthier cases. Peri-
operative antibiotics were continued for the ﬁrst 24 hours
postoperatively. Patients received preoperative systemic
antibiotics either alone (group A) or in conjunction with
intraoperative wound application of 1 g of vancomycin
powder and irrigation (group B) at the surgeon’s discre-
tion. Half of the dose was dispersed in powder form on
the inguinal wound bed before closure, and the other
half was mixed with 500 cc of normal saline and used to
irrigate the wound throughout the procedure.
Baseline demographics, clinical characteristics, and
operative details were obtained from the medical records.
Past medical history of coronary artery disease (CAD), dia-
betes mellitus, hypertension, hyperlipidemia, chronic ob-
structive pulmonary disease (COPD), current smoking,
previous smoking, chronic renal insufﬁciency, end-stage
renal disease, steroid use, or clopidogrel use was recorded.1079
Table I. Patient demographic and clinical characteristics
Variablea
Group A
(n ¼ 211)
Group B
(n ¼ 243)
P
value
Gender, male/female 210/1 240/3 .627
Age, mean (SD), years 65 (7.0) 65 (7.3) 1
Race
African American 56 (26.5) 60 (24.7) .667
Caucasian 139 (65.9) 163 (67.1) .842
Hispanic/other 16 (7.6) 20 (8.2) .862
Nasal MRSA 14 (6.7) 15 (6.1) .701
BMI, mean (SD), kg/m2 25.4 (5.2) 25.9 (5.0) .286
CAD 92 (43.6) 121 (49.8) .220
DM 85 (40.3) 103 (42.4) .703
IDDM 45 (21.3) 52 (22.2) 1
Hypertension 183 (86.7) 226 (93.0) .028
Hyperlipidemia 161 (76.3) 197 (81.1) .104
COPD 56 (26.5) 62 (25.5) .831
Current smoking 135 (64.0) 151 (62.1) .698
Previous smoking (>6 months) 187 (88.6) 222 (91.4) .349
Chronic renal insufﬁciencyb 24 (11.4) 30 (12.3) .773
Albumin,c mean (SD), g/dL 3.52 (0.59) 3.55 (0.59) .638
Systemic steroidsc 3 (1.4) 4 (1.6) 1.00
Clopidogrelc 42 (20.0) 55 (22.6) .493
BMI, Body mass index; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; IDDM, insulin-
dependent diabetes mellitus; MRSA, Methicillin-resistant Staphylococcus
aureus; SD, standard deviation.
aCategorical values are represented as n (%). Continuous values are
represented as mean (SD).
bEstimated glomerular ﬁltration rate <60 mL/min per 1.73 m2.
cPreoperative.
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determined and recorded. Previous smoking was deﬁned
as cessation more than 6 months before the operative
date. Chronic renal insufﬁciency was deﬁned as estimated
glomerular ﬁltration rate <60 mL/min per 1.73 m2.
Wound site infection and dehiscence over a 30-day
period were recorded. Involvement of the dermis and
subcutaneous tissue constituted a superﬁcial wound infec-
tion or dehiscence, whereas extension to the fascia level
was deﬁned as a deep wound complication.
Descriptive statistics were used to assess demographics,
comorbidities, and operative parameters. A two-tailed
Fisher exact test was used to compare characteristics for
categorical variables and two-tailed t-test for normally
distributed continuous variables. Multivariate regression
analysis was performed to adjust for confounders and iden-
tify potential risk factors for developing wound complica-
tions. P < .05 was considered signiﬁcant. The analyses
were carried out using Stata (version 11.2; StataCorp,
College Station, Tex).
RESULTS
Both groups had similar demographics and clinical
characteristics (Table I). There were 211 patients in group
A and 243 patients in group B. No signiﬁcant difference
in the prevalence of comorbidities, such as CAD, diabetes
mellitus, hyperlipidemia, COPD, current smoking, previous
smoking, chronic renal insufﬁciency, or perioperative sys-
temic steroid or clopidogrel use, was noted between the
two groups. There was a higher prevalence of hypertension
in group B (86.7% vs 93%; P¼ .028). The difference in nasal
MRSA prevalence was not signiﬁcant between the groups
(6.1% vs 6.7%; P ¼ .701).
There was no signiﬁcant difference in the distribution of
vascular procedure type, conduit type, operative blood loss,
or perioperative blood transfusion rates between the two
groups. However, the mean operative time was longer in
group B (263 minutes vs 299 minutes; P < .001; Table II).
Preoperative antibiotic prophylaxis was similarly distributed
between the groups, with the majority of patients in either
group having received intravenous vancomycin (92.9% vs
95.5%; P ¼ .311; Table III). Alternative antibiotics, such as
b-lactams or carbapenems, were administered in the event
of patient allergy or when concurrent coverage for unrelated
concomitant infections was necessary.
Looking at 30-day wound complication rates (Fig),
a total of 53 patients in group A (25.1%) developed either
superﬁcial or deep wound infections compared with
42 patients in group B (17.2%; P ¼ .049). The difference
was primarily due to group A demonstrating a higher
rate of superﬁcial infections than group B (18.9% vs
11.5%, respectively; P ¼ .033). There was no signiﬁcant
difference in deep wound infection rates between groups
A and B (6.1% vs 5.7%, respectively; P ¼ .692).
Overall wound dehiscence was observed more com-
monly in group A patients (22.2%) than in group B
(17.7%), but the difference did not reach statistical signiﬁ-
cance (P ¼ .239). The majority of the cases recorded weredue to superﬁcial dehiscence (21.3% vs 15.2%; P ¼ .113),
whereas deep dehiscence was far less common for groups
A and B (0.9% vs 2.4%; P ¼ .306). Early prosthetic conduit
explantation was required in two group A patients and
three group B patients. No major amputations were per-
formed in the 30-day postoperative period as a result of
wound complication.
In approximately 23% of all cases, there was history of
prior open surgery involving the ipsilateral inguinal area.
Subgroup analysis showed no signiﬁcant difference between
the reoperated patients and ﬁrst-time operated patients with
regard to superﬁcial infections (12% vs 17.3%; P ¼ .502),
superﬁcial dehiscence (23% vs 19%; P ¼ .374), or deep
dehiscence (1% vs 1.9%; P ¼ 1.0). However, there was
higher rate for deep infections for the reoperated patients
overall (13.1% vs 3.5%; P ¼ .020) without difference
between groups A and B (6.6% vs 5.3%; P ¼ .691).
Bacteriologic data obtained from wound cultures
demonstrated balanced distribution between the groups
(Table IV). The majority of documented infections in
both groups were due to gram-negative organisms
(13.2% vs 14.3%; P ¼ .574) followed by MRSA and other
gram-positive cocci. In a signiﬁcant number of cases (54%),
empiric antibiotic treatment was instituted after clinical
diagnosis of superﬁcial wound complications.
On multivariate analysis, there was an increased risk of
infection among patients with COPD (odds ratio [OR],
1.78; P ¼ .024) and increased body mass index (BMI)
(OR, 1.09; P < .001; Table V). There was also an even
Table II. Operative variables and conduit types
Variablea Group A (n ¼ 211) Group B (n ¼ 243) P value
Operative time, mean (SD), minutes 263 (117) 299 (113) <.001
Estimated blood loss, mean (SD), mL 360 (347) 379 (112) .538
Perioperative transfusion,b mean (SD) 1.9 (2.2) 2.2 (2.2) .171
Surgery type (open)
Aortofemoral 33 (15.6) 37 (15.2) 1
Infrainguinal 178 (84.4) 206 (84.8) 1
Conduit type
Prosthetic 54 (25.7) 81 (33.3) .081
Vein 94 (44.5) 93 (38.3) .182
Patch (bovine) 28 (13.2) 30 (12.3) .673
Cryopreserved 35 (16.6) 39 (16.1) .899
SD, Standard deviation.
aCategorical values are represented as n (%). Continuous values are represented as mean (SD).
bRepresented in units of packed red blood cells.
Table III. Preoperative intravenous antibiotic
prophylaxis
Variable
Group A
(n ¼ 211)
Group B
(n ¼ 243) P value
Vancomycin 196 (92.9) 232 (95.5) .311
Cefazolin 7 (3.3) 7 (2.9) .588
Piperacillin/tazobactam 1 (0.5) 3 (1.2) .627
Ampicillin/sulbactam 3 (1.4) 0 .099
Ampicillin 1 (0.5) 0 .464
Ciproﬂoxacin 0 1 (0.4) 1
Clindamycin 2 (0.9) 0 .214
Ertapenem 1 (0.5) 0 .464
Values are represented as n (%).
Fig. Comparative rates for 30-day postoperative superﬁcial and
deep inguinal wound infection and dehiscence.
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2.41; P < .001) or increased BMI (OR, 1.10; P < .001) as
well as a trend toward dehiscence among those with
chronic kidney disease (OR, 1.78; P ¼ .092). Patients diag-
nosed with CAD, while undergoing optimal medical
therapy, were found to be at decreased risk from dehis-
cence (OR, 0.58; P ¼ .003). Variables such as antibiotic
dose, procedure type, conduit type, blood loss or transfu-
sion, diabetes mellitus, and other comorbidities listed
in Table I were not found to be signiﬁcant predictors of
wound complications.
DISCUSSION
Vancomycin is a bactericidal glycopeptide that inhibits
cell wall synthesis by binding to a D-alanyl-D-alanine cell
wall precursor necessary for peptidoglycan cross-linking.
Utilization of this agent has increased dramatically due to
the growing prevalence of methicillin-resistant staphylo-
coccal infections. However, limited data are available
regarding its concentration in biological ﬂuids other than
plasma. Vancomycin is widely distributed to most tissues,
with an approximate volume of distribution of 0.4 to
1 L/kg, and about 50% of it is protein bound. It is not
metabolized and is primarily excreted unchanged in the
urine via glomerular ﬁltration.3 Topical vancomycin has
been hypothesized to achieve a higher local concentrationof antibiotic avoiding toxic systemic doses, and decreasing
the risk of associated bacterial resistance.4 However, the
degree to which vancomycin is absorbed systemically
when applied in this topical fashion is fairly variable.5,6
There are data supporting the use of local vancomycin
for the prevention of sternal wound infections in cardiac
surgery. Vander Salm et al2 ﬁrst reported in 1989 the use
of topical vancomycin applied to the sternum before skin
closure in a blinded, prospective, randomized trial involving
416 cardiac surgery patients. There was a signiﬁcant reduc-
tion in the incidence of sternal infections from3.6% to 0.45%
in the group receiving topical vancomycin (P ¼ .02). Infec-
tion also correlated with longer operative times. A prospec-
tive single-arm study by Desmond et al5 studied the effect of
topical vancomycin before sternotomy closure on systemic
vancomycin levels in 14 patients undergoing elective coro-
nary artery bypass graft procedures. Serum levels were
measured at 30, 60, 120, 180, and 720minutes. They found
that topical vancomycin administration correlated with
detectable although subtherapeutic systemic vancomycin
levels for up to 5 days postoperatively. In another study,
Lazar et al6 concluded that the use of topical vancomycin
applied to the sternotomy incision did not potentiate the
Table IV. Microbiology of 30-day wound infections
Variable
Group A
(n ¼ 53)
Group B
(n ¼ 42) P value
MRSA 1 (1.9) 2 (4.8) 1
GPC (other) 5 (9.5) 4 (9.5) .517
GNR 7 (13.2) 6 (14.3) .574
Negative cultures 4 (7.5) 3 (7.1) .704
Mixed skin ﬂora 7 (13.2) 4 (9.5) .229
Clinical diagnosisa 29 (54.7) 23 (54.8) .136
GNR, Gram-negative rods; GPC, gram-positive cocci; MRSA, methicillin-
resistant Staphylococcus aureus.
Values are represented as n (%).
aNo cultures obtained, empiric treatment instituted.
Table V. Multivariate analysis of risk factors for 30-day
postoperative inguinal wound infection (A) and
dehiscence (B)a
A
Variable OR 95% CI P value
BMI 1.09 1.04-1.14 <.001
COPD 1.78 1.08-2.95 .024
B
Variable OR 95% CI P value
BMI 1.1 1.04-1.15 <.001
CAD .58 .35-.97 .003
COPD 2.41 1.44-4.03 .001
CKD 1.78 .91-3.46 .092
BMI, Body mass index; CAD, coronary artery disease; CI, conﬁdence
interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmo-
nary disease; OR, odds ratio.
aAdjusted for operative variables and comorbidities.
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icantly to postoperative renal toxicity.
In the neurosurgical literature, direct deposition of
vancomycin powder has been reported to signiﬁcantly
reduce the incidence of infection in patients undergoing
posterior spine stabilization for traumatic spine injuries as
well as other neurosurgical spine procedures.7,8 The ortho-
pedic literature also supports the use of local antibiotics
in the form of cement beads or via orthopedic implants
for the treatment of infected open fractures and osteo-
myelitis.9,10 In vitro studies have also demonstrated that
such delivery media avoid high concentrations of anti-
biotics, which would otherwise inhibit bone healing.11 In ad-
dition, animal model studies evaluating the effectiveness of
sustained-release vancomycin sheets, vancomycin-delivering
glycerylmonostearate implants, or vancomycin-coated mesh
have also demonstrated signiﬁcantly reduced rates of bacterial
growth in the presence of local antibiotics.12-14
Currently, it is unknown whether local vancomycin
treatment has any effect on wound complications after
vascular procedures. The reported incidence of surgical
wound infections after vascular surgery ranges from 2% for
open or endovascular aortic interventions to as high as
20% after lower limb bypass grafting procedures.1 Wound
infections may dramatically increase health care resource
utilization and further increase morbidity, especially in
patients with vascular reconstructions. Deep infections and
dehiscence risk exposure of underlying vascular grafts and
may necessitate graft removal or at least multiple procedures
if graft salvage is pursued.15 With the high cost of managing
the sequelae of postoperative wound complications and
the health care system’s growing emphasis on paying for
performance, it is important to investigate methods of
reducing such complications.
Our study showed a 7.9% decrease in overall inguinal
wound infection rates for the local vancomycin therapy
group. This difference mainly reﬂects a positive impact on
superﬁcial infections as the decrease in deep infection rates
was 0.4% and not statistically signiﬁcant. In a similar
fashion, the trend toward a decrease in overall dehiscence
by 4.5% for the local vancomycin group was not statistically
signiﬁcant and was driven primarily by superﬁcial dehis-
cence events.The beneﬁt of local vancomycin in our cohort was
small and related to superﬁcial wound complications, which
is in contrast to the beneﬁt reported in median sternotomy
studies. This may be due to differences between sternal and
inguinal wound characteristics. The former has a rich
vascular supply involving the sternal bone marrow and
crossing pectoralis major muscle ﬁbers, whereas the latter
is primarily composed of subcutaneous adipose and
lymphatic tissue. The decreased vascularity encountered
in the inguinal wounds could result in poor systemic
absorption of the local antibiotic compared with median
sternotomy wounds.
Another contributing factor to the blunted compara-
tive beneﬁt of local vancomycin observed in our series
could be that the majority of patients received preoperative
intravenous vancomycin due to the increased prevalence
of MRSA in our institution’s patient population (6.3%).
Approximately half of the infections, all of which were
superﬁcial, were diagnosed and treated empirically with
gram-positive coverage antibiotics. For the remainder of
superﬁcial infections, as well as all deep complications in
either group, gram-negative organisms were identiﬁed as
the most common pathogens followed by gram-positive
cocci.
Factors associated with increased risk of both infection
and dehiscence included BMI and history of COPD. We
found a 9% risk increase per 1 kg/m2 of BMI above
normal. It is possible that obese patients are prone to
inguinal complications due to compromised local hygiene,
need for deeper lymphatic bed dissection to expose femoral
vessels, and increased lateral wound traction forces as noted
by other authors as well.16,17 Underlying pathologic corre-
lation in patients with COPD and chronic kidney disease
seems more complex, as these patients also have impaired
immune response and wound healing.16,18,19 The protec-
tive effect seen in patients with CAD is likely indirect and
JOURNAL OF VASCULAR SURGERY
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in that subgroup of patients.
Limitations of the present study should be mentioned.
It is a retrospective study focusing on wound complications
within the 30-day postoperative period, not accounting
for possible late infections. However, the incidence is
expected to be very low because most surgical wounds are
completely healed by this point. Local vancomycin was
administered at the surgeon’s discretion, which may have
introduced selection bias, although both groups had
balanced distribution of clinical and operative variables.
Serum vancomycin levels were not measured in our patients;
thus, the rate of absorption and bioavailability cannot be
determined for the speciﬁc wound bed application.
CONCLUSIONS
Our study demonstrates that the addition of intraoper-
ative local vancomycin did not improve the rates of inguinal
wound dehiscence or deep infections but did have a positive
impact on superﬁcial wound infections and might be
considered in high-risk patients. Modiﬁcation of identiﬁed
risk factors may further decrease the incidence of inguinal
wound complications. A prospective randomized study is
needed to further evaluate the role of local vancomycin
treatment on inguinal wound outcomes.
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